Any new or unusual symptom after dosing. Because this compound has little or no human safety data, there is no established list of 'expected' effects to reassure you against — treat anything abnormal as a signal.
Stop at the first clearly abnormal reaction and reassess. Keep the vial and lot number in case you need to describe what you actually took.
Any severe or fast-worsening symptom — difficulty breathing, chest pain, fainting, severe pain — is a 911 call regardless of the compound.
Allergic reaction: hives, swelling of the lips, tongue or throat, wheezing or dizziness can escalate to anaphylaxis within minutes — call 911 immediately. Site infection: spreading redness, heat, swelling, pus or fever is not wait-and-see; an abscess or cellulitis can need drainage or IV antibiotics. Unverified product: grey-market vials are frequently mislabelled or contaminated, so a reaction may be to endotoxin or the wrong contents, not the named compound.
The full-length molecule, and the one the actual research concerns — a distinction routinely blurred by vendors selling “TB-500”. It is among the most abundant proteins in most cells, binding monomeric G-actin and regulating the polymerisation that drives cell migration. Its effects on angiogenesis, keratinocyte migration and inflammation follow from that role.
Reached genuine clinical trials — phase 2 in dry eye disease, venous stasis ulcers and epidermolysis bullosa — which is more than TB-500 can claim. Results were insufficient to carry it to approval. Extensive preclinical work in cardiac and corneal repair.
Not FDA-approved. Development discontinued. Prohibited in sport (WADA S0).
Trial safety data exist at studied exposures. The pro-angiogenic mechanism carries the same unresolved theoretical concern as BPC-157 — an agent that promotes vessel growth does not choose which tissue benefits.
The full-length protein reached phase 2 (dry eye, venous ulcers, epidermolysis bullosa) at study-defined doses; results did not support approval. No established therapeutic regimen.
Reported from clinical trials or FDA labelling as a matter of record. It is not a recommendation, and for unapproved compounds no dose has been shown safe or effective in humans.
Above is what was administered in trials or on FDA labels, reported as fact. We do not convert it into a personal protocol, calculate a dose for your body weight, or tell you what to inject or how to reconstitute it — that decision belongs with a licensed physician. See our editorial policy.
Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.